| 摘要 |
FIELD: medicine; surgery. ^ SUBSTANCE: cost-effectiveness analysis of antihypertensive pharmacotherapy results is ensured by formula: ^ ^ Therein is profitability that is cost-effectiveness of antihypertensive pharmacotherapy results, in points. E is clinical effectiveness of antihypertensive therapy: E=1, if desired systolic and diastolic pressures are measured up; E=2, if desired systolic arterial pressure is measured up, while diastolic arterial pressures is not, or any arterial pressure is reduced by 20% and more of the reference value, and desired arterial pressure is not measured up though; E=3, if desired systolic and diastolic arterial pressures are not measured up, or any arterial pressure is reduced by less than 20% of the reference value. O(neg) is deterioration after antihypertensive therapy being performed comparatively to any previous monitored laboratory parametre. S(neg) is health deterioration noticed by the patients in relation to antihypertensive therapy being performed. O(pos) is the absence of deterioration or recorded improvement comparatively to any previous monitored laboratory parametre. S(pos) is the absence of health deterioration or health improvement noticed by the patients in relation to antihypertensive therapy being performed. If factors meeting the conditions of criteria O(neg), S(neg), O(pos), S(pos) are observed, 1 point is assigned to the respective criterion, while said factors are not observed, 0 points are assigned. t is intake multiplicity of each antihypertensive agent a day. mmax is a maximum daily dose of each antihypertensive agent. n is a number of taken antihypertensive agents. Cv is a unit price of each antihypertensive agent in roubles per on the day of purchase. d1 is amount of reactant in a daily dose of each antihypertensive agent, mg; v is a quantity of tablets in a case; d is amount of reactant in a tablet for each antihypertensive agent. The estimated profitability not exceeding 1 point indicates a good therapy, while adequate therapy is interpreted with profitability 1 to 10 points, and 10 points and more show inadequate therapy. ^ EFFECT: optimisation of pharmacotherapy expenses for the patients suffering from hypertension. ^ 1 ex |
